| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6087262 | Clinical Immunology | 2016 | 12 Pages |
Abstract
These data suggest that sema3A and sema7A are involved in the pathogenesis of EAE, in the modulation of the immune response and in the neurodegeneration that take place in the CNS. Sema7A may represent an intriguing potential therapeutic target for the treatment of both the neurodegenerative and immune-mediated disease processes in MS.
Keywords
NDSKlüver–BarreraPlatelet-derived growth factor APPIBNatural regulatory T cellsPLXNp.i.pdgfaphorbol-12-myristate 13-acetatenTregGPiEAEPFAOPCCFADABPBSFBSMOG3,3′-diaminobenzidinecomplete Freund's adjuvantBSAPMAbovine serum albuminexperimental autoimmune encephalomyelitisCNSfoetal bovine serumnormal donkey serumoligodendrocyte precursor cellcentral nervous systemPhosphate buffered salinegrey matterMultiple sclerosishaematoxylin and eosinparaformaldehydeplexinglycophosphatidylinositolmyelin oligodendrocyte glycoprotein
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ana Gutiérrez-Franco, Carme Costa, Herena Eixarch, Mireia Castillo, Eva M. Medina-RodrÃguez, Ana Bribián, Fernando de Castro, Xavier Montalban, Carmen Espejo,